Table 3: Comparison of epidemiological, clinical and treatment data in psoriatic arthritis patients with and without depression and correlation of depression with quality of life, age, disease duration and activity indexes.
|
COMPARISON STUDIES |
||||
|
|
With depression n = 28 (51.8%) |
Without depression n = 26 (48.1%) |
P |
|
|
Females/Males |
15/13 |
12/14 |
0.58 |
|
|
Tobacco exposure |
15 (53.3%) |
13 |
0.79 |
|
|
Polyarthritis |
10 (35.7%) |
4 (15.3%) |
0.42 |
|
|
Oligoarthritis |
14 (50%) |
16 (61.5%) |
||
|
Axial |
12 (42.8%) |
12 (46.1%) |
||
|
Distal interphalangeal |
2 (7.1%) |
3 (11.5%) |
||
|
Treatment |
||||
|
DMARDs (Methotrexate + leflunomide) |
18 (64.2%) |
16 (61.5%) |
0.83 |
|
|
Anti-TNF-alpha |
9 (32.1%) |
9 (34.6%) |
0.84 |
|
|
CORRELATION STUDIES OF CES-D QUESTIONNAIRE RESULTS |
||||
|
|
Rho |
95% Confidence interval |
P |
|
|
Age |
0.18 |
-0.09 to 0.43 |
0.18 |
|
|
Arthritis duration |
-0.008 |
-0.28 to +0.27 |
0.95 |
|
|
Psoriasis duration |
-0.004 |
-0.32 to +0.23 |
0.73 |
|
|
PASI |
0.50 |
+0.27 to +0.68 |
< 0.0001 |
|
|
ASDAS -ESR |
0.26 |
-0.01 to +0.50 |
0.057 |
|
|
ASDAS-CRP |
0.17 |
-0.10 to +0.43 |
0.20 |
|
|
CRP |
-0.04 |
-0.32 to +0.23 |
0.73 |
|
|
ESR |
0,14 |
-0.14 to 0.40 |
0.31 |
|
|
SF-12 (physical domain) |
-0.55 |
-0.71 TO -0.32 |
< 0.0001 |
|
|
SF-12 (mental domain) |
-0.80 |
-0.88 to -0.68 |
< 0.0001 |
|
DMARDs: Disease Modifying Rheumatic Drugs; PASI: Psoriasis Area Severity Index; ASDAS: Ankylosing Spondylitis Disease Score; ESR: Erythrocyte Sedimentation Rate; CRP: C Reactive Protein; SF-12: Short Form health survey with 12 questions; CES-D: Center for Epidemiologic Studies Depression scale